Insider Trading April 17, 2026 05:44 PM

Processa Pharmaceuticals Officer Buys $4,065 of PCSA Stock; Holds Rise After Purchase

Chief Business - Strategy Officer Patrick Lin adds 1,369 shares to his stake as the shares trade above the purchase price

By Hana Yamamoto PCSA
Processa Pharmaceuticals Officer Buys $4,065 of PCSA Stock; Holds Rise After Purchase
PCSA

Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, purchased 1,369 shares on April 15, 2026, for $2.97 per share, a $4,065 transaction. The stock currently trades at $3.10, up roughly 12% over the past week but still down 59% over six months. An analysis cited in the filing notes a price target of $25, suggesting the company may be undervalued at current levels.

Key Points

  • Patrick Lin bought 1,369 shares of Processa Pharmaceuticals on April 15, 2026, at $2.97 per share, totaling $4,065.
  • After the trade, Lin directly holds 4,725 shares and indirectly holds 1,740 shares through the Lin Family Trust (dated Feb 4, 2024).
  • Processa shares traded at $3.10 at the time of the report, up nearly 12% over the prior week but down 59% over six months; a cited analysis shows a $25 analyst price target, implying potential undervaluation.

An insider purchase filed for Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) shows Patrick Lin, the company's Chief Business - Strategy Officer, acquired 1,369 shares of common stock on April 15, 2026. The transaction was executed at a per-share price of $2.97, bringing the total outlay to $4,065.

At the time of the filing, Processa's shares were trading at $3.10. That level reflects a near 12% rise over the prior week, though the stock remains substantially lower over a longer horizon - down 59% over the past six months.

The disclosure also cites an analysis indicating the stock appears undervalued at current levels, with analysts setting a price target of $25. Following the April 15 purchase, Lin's direct ownership in Processa totals 4,725 shares. In addition to those directly held shares, Lin indirectly holds 1,740 shares through the Lin Family Trust dated Feb 4, 2024, as reported in the filing.


Context and immediate implications

Insider buying can be interpreted in multiple ways by market participants; in this instance, the filing documents a modest purchase size by a senior strategy executive. The transaction raises the insider's direct stake but does not, by itself, change overall ownership materially.

The filing's note about valuations and the cited $25 price target highlights a significant gap between current trading levels and analyst expectations embedded in that analysis. The company-wide market move - up roughly 12% over the past week - has not closed that disparity.


Ownership snapshot

  • Shares purchased on April 15, 2026: 1,369
  • Price per share paid: $2.97
  • Total transaction value: $4,065
  • Shares trading at time of report: $3.10
  • Directly owned by Lin after transaction: 4,725 shares
  • Indirect holdings via Lin Family Trust (Feb 4, 2024): 1,740 shares

What is and is not shown by the filing

The filing documents the purchase, the resulting share counts, recent market moves and a referenced valuation view. It does not provide further commentary from company management or additional details on any planned future transactions.

Risks

  • Share price volatility - the stock is up nearly 12% over the past week but down 59% over six months, indicating significant price swings that affect investor risk in the healthcare and biotech sectors.
  • Limited disclosure - the filing records the purchase and ownership but does not include management commentary or details on any future insider activity, leaving uncertainty about the company's near-term plans.
  • Valuation gap - the cited $25 price target contrasts sharply with current trading levels, but the filing does not provide the underpinnings of that target, creating uncertainty for investors evaluating valuation in the pharmaceuticals sector.

More from Insider Trading

Aehr Test Systems Director Disposes $139,922 in Shares; Company Posts Record Order and Strong Bookings Apr 17, 2026 StandardAero HR Chief Sells $20.9K in Shares as Company Posts Strong Q4 2025 Results Apr 17, 2026 Apogee CFO Disposes $180,000 in Stock as Shares Trade Near Yearly High Apr 17, 2026 IBEX Director Disposes $162,809 in Shares Amid Active Buybacks and Strong Quarterly Results Apr 17, 2026 StandardAero Executive Disposes of $10,670 in Shares Amid Recent Option Grants and Strong Q4 Results Apr 17, 2026